Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly.
Acromegaly
/ metabolism
Adult
Blood Glucose
/ metabolism
Case-Control Studies
Diabetes Mellitus, Type 2
/ metabolism
Female
Gastric Inhibitory Polypeptide
/ metabolism
Glucagon
/ metabolism
Glucagon-Like Peptide 1
/ metabolism
Glucose Clamp Technique
Humans
Hyperglycemia
/ metabolism
Incretins
/ pharmacology
Insulin
/ metabolism
Insulin Resistance
/ physiology
Insulin-Secreting Cells
/ metabolism
Male
Prospective Studies
Receptors, Gastrointestinal Hormone
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 04 2019
04 04 2019
Historique:
received:
31
05
2018
accepted:
20
03
2019
entrez:
6
4
2019
pubmed:
6
4
2019
medline:
28
10
2020
Statut:
epublish
Résumé
Impaired insulin sensitivity (IS) and β-cell dysfunction result in hyperglycaemia in patients of acromegaly. However, alterations in incretins and their impact on glucose-insulin homeostasis in these patients still remain elusive. Twenty patients of active acromegaly (10 each, with and without diabetes) underwent hyperinsulinemic euglycaemic clamp and mixed meal test, before and after surgery, to measure indices of IS, β-cell function, GIP, GLP-1 and glucagon response. Immunohistochemistry (IHC) for GIP and GLP-1 was also done on intestinal biopsies of all acromegalics and healthy controls. Patients of acromegaly, irrespective of presence or absence of hyperglycaemia, had similar degree of insulin resistance, however patients with diabetes exhibited hyperglucagonemia, and compromised β-cell function despite significantly higher GIP levels. After surgery, indices of IS improved, GIP and glucagon levels decreased significantly in both the groups, while there was no significant change in indices of β-cell function in those with hyperglycaemia. IHC positivity for GIP, but not GLP-1, staining cells in duodenum and colon was significantly lower in acromegalics with diabetes as compared to healthy controls possibly because of high K-cell turnover. Chronic GH excess induces an equipoise insulin resistance in patients of acromegaly irrespective of their glycaemic status. Dysglycaemia in these patients is an outcome of β-cell dysfunction consequent to GIP resistance and hyperglucagonemia.
Identifiants
pubmed: 30948746
doi: 10.1038/s41598-019-41887-7
pii: 10.1038/s41598-019-41887-7
pmc: PMC6449401
doi:
Substances chimiques
Blood Glucose
0
Incretins
0
Insulin
0
Receptors, Gastrointestinal Hormone
0
Gastric Inhibitory Polypeptide
59392-49-3
Glucagon-Like Peptide 1
89750-14-1
Glucagon
9007-92-5
gastric inhibitory polypeptide receptor
D6H00MV7K8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5646Références
Diabetes Care. 2001 Sep;24(9):1640-5
pubmed: 11522713
J Clin Endocrinol Metab. 2013 Aug;98(8):3446-53
pubmed: 23733372
Diabetes. 2009 Jun;58(6):1342-9
pubmed: 19276444
Clin Endocrinol (Oxf). 2000 May;52(5):549-55
pubmed: 10792333
J Biol Chem. 2001 Jul 13;276(28):25889-93
pubmed: 11342531
Lancet Diabetes Endocrinol. 2016 Jun;4(6):525-36
pubmed: 26876794
Endocr J. 1997 Aug;44(4):617-20
pubmed: 9447299
Am J Physiol. 1986 Mar;250(3 Pt 1):E269-73
pubmed: 3513613
J Clin Endocrinol Metab. 1991 May;72(5):1048-53
pubmed: 2022706
Exp Biol Med (Maywood). 2002 Mar;227(3):149-57
pubmed: 11856812
J Clin Endocrinol Metab. 1982 May;54(5):1033-8
pubmed: 7037819
Trends Endocrinol Metab. 2016 Jul;27(7):470-483
pubmed: 27229934
J Clin Endocrinol Metab. 1983 Apr;56(4):733-8
pubmed: 6339536
Diabetologia. 2011 Jan;54(1):10-8
pubmed: 20871975
Pituitary. 2017 Feb;20(1):46-62
pubmed: 28224405
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
pubmed: 25356808
J Korean Med Sci. 2012 Feb;27(2):177-83
pubmed: 22323865
Diabetes. 2007 Jun;56(6):1551-8
pubmed: 17360984
Endocr Rev. 2004 Feb;25(1):102-52
pubmed: 14769829
Horm Res. 2004;62 Suppl 3:51-5
pubmed: 15539799
Mol Cell Biol. 2004 Jun;24(12):5434-46
pubmed: 15169905
J Clin Endocrinol Metab. 2004 Nov;89(11):5448-53
pubmed: 15531496
J Clin Endocrinol Metab. 1998 Mar;83(3):744-50
pubmed: 9506719
J Clin Endocrinol Metab. 2009 May;94(5):1500-8
pubmed: 19208728
Exp Clin Endocrinol Diabetes. 2007 May;115(5):308-16
pubmed: 17516294
Horm Res. 1991;36 Suppl 1:32-5
pubmed: 1806481
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
J Biol Chem. 1998 Jun 19;273(25):15719-26
pubmed: 9624169
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):419-24
pubmed: 11752399
J Exp Med. 2001 Jan 15;193(2):263-9
pubmed: 11208867
J Clin Endocrinol Metab. 1970 Mar;30(3):288-92
pubmed: 5412539
Diabetologia. 2013 May;56(5):965-72
pubmed: 23377698
Endocr Rev. 1987 May;8(2):115-31
pubmed: 3301316
Diabetes. 2007 Jun;56(6):1638-46
pubmed: 17363744
J Clin Endocrinol Metab. 1992 May;74(5):1012-9
pubmed: 1569148
Diabetologia. 2007 Nov;50(11):2342-7
pubmed: 17846745
Diabetes Care. 2013 Oct;36(10):3346-52
pubmed: 24065842
Trends Endocrinol Metab. 2016 Apr;27(4):226-237
pubmed: 26948712
Eur J Endocrinol. 2001 Jul;145(1):R1-4
pubmed: 11415859
Eur J Endocrinol. 2017 May;176(5):543-553
pubmed: 28179449